Search Result

Results for "

pd-1-antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (7) CD38 (1) Interleukin Related (2) LAG-3 (1) Liposome (1) MAP4K (1) P-glycoprotein (1) Phosphodiesterase (PDE) (1) Prostaglandin Receptor (1) STING (1)
By Research Areas:	Cancer (12) Infection (1) Inflammation/Immunology (5)

Inhibitors & Agonists

Inhibitory Antibodies

Antibodies

Targets Recommended: PD-1/PD-L1 ADC Antibody Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990824

Anti-Mouse PD-1 Antibody (J43)	PD-1/PD-L1	Others
Anti-Mouse PD-1 Antibody (J43) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to *PD-1. The recommend isotype control of Anti-Mouse PD-1* Antibody (J43): Armenian hamster IgG, Isotype Control (HY-P990305).

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001)	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse *PD-1* IgG1 antibody inhibitor.

HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody is an anti-mouse *PD-1* IgG2a antibody inhibitor.

HY-P99118

Serplulimab HLX 10	PD-1/PD-L1	Cancer
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1* antibody*. Serplulimab can be used in research of small cell lung cancer ^[1].

HY-128481

SB24011	STING	Cancer
SB24011 is a STING-TRIM29 interaction inhibitor with a IC₅₀ value of 3.85 μM. SB24011 enhances STING immunity by upregating STING protein levels, thereby enhancing the immunotherapy effect of STING agonists and anti-PD-1 antibodies through systemic anticancer immunity ^[1].

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) ^[1].

HY-P991079

Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research ^[1].

HY-168147

Enpp-1-IN-24	Phosphodiesterase (PDE)	Cancer
Enpp-1-IN-24 (compund 7) is an *ENPP1* inhibitor that, in combination with anti-PD-1 antibodies, achieves 77.7% tumor growth inhibition and improves survival in mouse models ^[1].

HY-168528

WS-917	P-glycoprotein	Cancer
WS-917 is a potent and orally active *ABCB1* modulator. WS-917 enhances ABCB1 ATPase activity. WS-917 significantly enhances the antitumor effect of paclitaxel combined with anti-PD-1 antibody. WS-917 promotes CD8 ⁺ T-cell activation ^[1].

HY-P99100

Visugromab 1 Publications Verification CTL-002	PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors ^[1].

HY-172107

HPK1-IN-56	MAP4K Interleukin Related	Inflammation/Immunology Cancer
HPK1-IN-56 (Compound A29) is a *HPK1* inhibitor (IC₅₀: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC₅₀: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody ^[1].

HY-P99744

Modakafusp alfa TAK-573	CD38	Inflammation/Immunology Cancer
Modakafusp alfa (TAK-573) is a humanized, *anti-CD38* IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice ^[1] .

HY-169480

Lipid C2	Liposome	Infection Cancer
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model ^[1].

HY-169859

EP4 receptor antagonist 7	Prostaglandin Receptor Interleukin Related	Inflammation/Immunology Cancer
EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC₅₀ value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC₅₀ value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD ⁸⁺ T cells into tumors in a CT26 murine colon cancer model ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P990824

Anti-Mouse PD-1 Antibody (J43)	PD-1/PD-L1	Others
Anti-Mouse PD-1 Antibody (J43) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to *PD-1. The recommend isotype control of Anti-Mouse PD-1* Antibody (J43): Armenian hamster IgG, Isotype Control (HY-P990305).

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001)	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse *PD-1* IgG1 antibody inhibitor.

HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody is an anti-mouse *PD-1* IgG2a antibody inhibitor.

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	Inhibitory Antibodies	Others
Anti-Mouse PD-1 Antibody (29F.1A12) is a kind of rat IgG2a kappa in vivo mouse antibody, targeting to *PD-1. The recommend isotype control of Anti-Mouse PD-1* Antibody (29F.1A12): Rat IgG2a kappa, Isotype Control (HY-P990679).

HY-P99118

Serplulimab HLX 10	PD-1/PD-L1	Cancer
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1* antibody*. Serplulimab can be used in research of small cell lung cancer ^[1].

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) ^[1].

HY-P99100

Visugromab 1 Publications Verification CTL-002	PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors ^[1].

HY-P99744

Modakafusp alfa TAK-573	CD38	Inflammation/Immunology Cancer
Modakafusp alfa (TAK-573) is a humanized, *anti-CD38* IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice ^[1] .

HY-P991079

Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research ^[1].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81169A

	PD-1 Antibody(YA3401) Programmed cell death protein 1; CD279; CD279 antigen; hpd 1; hpd-1; hSLE1; pd 1; pd1; pdCD 1; pdCD1; pdCD1_HUMAN; Programmed cell death 1; Protein pd 1; Protein pd-1; SLEB2; Systemic lupus erythematosus susceptibility 2.	WB, IHC-P, ICC/IF, FC	Human
	PD-1 Antibody is an unconjugated, approximately 32 kDa, rabbit-derived, anti-PD-1 monoclonal antibody. PD-1 Antibody can be used for: WB, IHC-P, Flow-Cyt, IF/ICC expriments in human background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.